Your Global Leader in Stem Cell Market Research
RoosterBio recently hosted a webinar called “Planning a Successful MSC Therapy for Rapid COVID Response” to address challenges that mesenchymal stem/stromal cell (MSC) therapy developers might face to manufacture sufficient doses to treat COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) or other related indications.
While there is not yet an approved treatment for COVID-19, scientific, medical and regulatory agencies are making heroic efforts to bring out new medicines. Numerous COVID-19 product categories have emerged, including vaccines, antibodies, antivirals, repurposed drugs, RNA-based drugs, and cell-based therapies, as well as other approaches, such as enzymes, peptides and glycoproteins. [Read more…]
It’s official. Regenerative medicine (RM) companies are surging during COVID-19.
There are now 800+ companies developing regenerative medicine products for therapeutic use in humans — hundreds of which are contributing toward the management of the global COVID-19 pandemic. [Read more…]
HOUSTON, May 21, 2020 — FibroGenesis announced significant efficacy of its PneumoBlast™ product in an animal model of lung inflammation which resembles COVID-19. Mice immune systems were stimulated to enter hyper-activation mode, which causes symptoms similar to COVID-19. Once COVID-19 simulation was achieved, administration of PneumoBlast™ resulted in significant reduction in lung fluid accumulation. Additionally, reduction was observed from infiltration of inflammatory cells, as well as suppression of chemical mediators such as interleukin-6 (IL-6), which are associated with poor survival in COVID-19 patients. [Read more…]
